A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Commentary|Podcasts|July 1, 2025
An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial
Host Craig Beavers sits down with Kazuhiko Kido, PharmD, a clinical associate professor at the West Virginia University School of Pharmacy, to discuss intravenous iron and its use in patients with heart failure.
Advertisement
Host Craig Beavers sits down with Kazuhiko Kido, PharmD, a clinical associate professor at the West Virginia University School of Pharmacy, to discuss intravenous iron and its use in patients with heart failure, as well as findings from the FAIR-HF2 clinical trial.
Show notes:
- Anker SD, Friede T, Butler J, et al.
Intravenous ferric carboxymaltose in heart failure with iron deficiency . JAMA. 2025;333(22):1965-1976. doi:10.1001/jama.2025.3833 - Kido K, Fang W, Broscious R, et al.
Evaluation of a pharmacist-provider collaborative clinic for treatment of iron deficiency in patients with heart failure . Am J Health Syst Pharm. 2023;80(19):1326-1335. doi:10.1093/ajhp/zxad149 - Kido K, Beavers CJ, Dulnuan K, et al.
Management of iron deficiency in heart failure: practical considerations and implementation of evidence-based iron supplementation . JACC Heart Fail. 2024;12(12):1961-1978. doi:10.1016/j.jchf.2024.05.014 Scientific Statement on Diagnosis and Treatment of Iron Deficiency in Heart Failure Released by Heart Failure Society of America . News release. HFSA. May 2, 2023. Accessed June 27, 2025.- Antrim A.
Enhancing Patient Care in Heart Failure-Related Anemia Through Improved Communication, Monitoring, and Education . Pharmacy Times. March 17, 2025. Accessed June 27, 2025.
Advertisement
Related to this article
Neither the lipoprotein(a) [Lp(a)]–lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
The most enduring resources a preceptor can give students are the confidence and tools to ask deeper questions.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
FDA Grants Accelerated Approval to Ravulizumab for Proteinuria Reduction in IgA Nephropathy
4
Can AI Help Predict Drug Shortages?
5